ReviewBiomedicines2022
Exosomal MicroRNAs as Novel Cell-Free Therapeutics in Tissue Engineering and Regenerative Medicine.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Exosomal microRNAs in Periodontitis: From Molecular Footprints to Clinical Frontiers.ACS pharmacology & translational science · 2026Review
- Article
- Beyond miRNA Cargo Profiles: Anti-Inflammatory Roles of Extracellular Vesicle-Enriched miRNAs Derived From Human Intervertebral Disc Cells Unveiled by Functional Testing.Journal of extracellular biology · 2026Article
- Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders.Cellular and molecular neurobiology · 2026Review
- Glycyrrhizic acid combined with human adipose-derived MSCs synergistically alleviates the MPP+/MPTP-induced parkinson's disease by inducing autophagy through PI3K/AKT/HIF-1α pathway.Stem cell research & therapy · 2025Article
- Senotherapy for chronic lung disease.Pharmacological reviews · 2025Review
- Extracellular vesicles for the delivery of gene therapy.Nature reviews bioengineering · 2025Article
- Review
- Dendritic Cell Repression by TNF-α-Primed Exosomes Accelerate T2DM Wound Healing Through miR-146a-5p/TXNIP/NLRP3 Axis.International journal of nanomedicine · 2025Article
- Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.Translational neurodegeneration · 2024Review
- miRNAs: From Master Regulators of Gene Expression to Biomarkers Involved in Intercellular Communication.Biomedicines · 2024Article
- Research progress on the mechanism of exosome-mediated virus infection.Frontiers in cellular and infection microbiology · 2024Review
- Review
- Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer.Cancers · 2023Review
- Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?Frontiers in bioengineering and biotechnology · 2023Review
- Engineered extracellular vesicles as therapeutics of degenerative orthopedic diseases.Frontiers in bioengineering and biotechnology · 2023Review
- Correlation Between Endoglin and Malignant Phenotype in Human Melanoma Cells: Analysis of hsa-mir-214 and hsa-mir-370 in Cells and Their Extracellular Vesicles.Advances in experimental medicine and biology · 2023Article
- Neuronal and Glial Communication via Non-Coding RNAs: Messages in Extracellular Vesicles.International journal of molecular sciences · 2022Review
- Engineered Extracellular Vesicles in Arthritic Diseases: Therapeutic Applications & Challenges.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Extracellular vesicles (EVs) are membrane-bound vesicles (50-1000 nm) that can be secreted by all cell types. Microvesicles and exosomes are the major subsets of EVs that exhibit the cell-cell communications and pathological functions of human tissues, and their therapeutic potentials. To further understand and engineer EVs for cell-free therapy, current developments in EV biogenesis and secretion pathways are discussed to illustrate the remaining gaps in EV biology. Specifically, microRNAs (miRs), as a major EV cargo that exert promising therapeutic results, are discussed in the context of biological origins, sorting and packing, and preclinical applications in disease progression and treatments. Moreover, advanced detection and engineering strategies for exosomal miRs are also reviewed. This article provides sufficient information and knowledge for the future design of EVs with specific miRs or protein cargos in tissue repair and regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.